KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers.

Kyung Sik Park, Hyun-Soo Kim, Jung-Hwan Oh, Woo Chul Chung, Suck Chei Choi, Si Hyung Lee, Tae Ho Kim, Dae Young Cheung, Gwang Ho Baik, Sun Moon Kim, Hang Lak Lee, Jeong Seop Moon, Cheol Woong Choi, Chongil Sohn, Kyoung Oh Kim, Byung-Wook Kim, Hye-Kyung Jung, Da Hyun Jung, Sung Soo Kim, Moo In Park, Ju Yup Lee, Gwang Ha Kim, Hee Seok Moon, Hoonjai Chun, Ki-Nam Shim, Woon Geon Shin, Chan Hyuk Park, Taeoh Kim, Sung Woo Jung, Hyunjin Kim, Sam Ryong Jee, Keemyung Lee, Yu Kyung Cho, Sung Chul Park, Jinwoong Cho, Chealwung Huh, Hyesoo Kwon, Jun Kim, John Kim, Jong-Jae Park

Gut Liver 10.5009/gnl250334

PMID41540828
PMCID-
DOI10.5009/gnl250334
发表日期2026-01-16
摘要

摘要

BACKGROUND/AIMS: Zastaprazan (JP-1366) is a novel potassium-competitive acid blocker with a fast onset and prolonged duration. This study aimed to assess the efficacy and safety of zastaprazan versus lansoprazole in patients with gastric ulcers. METHODS: A total of 329 subjects with confirmed gastric ulcers participated in a phase 3, multicenter, randomized, double-blind, active-controlled clinical study. Subjects were randomized to receive zastaprazan 20 mg or lansoprazole 30 mg once daily up to 8 weeks. The primary endpoint was the cumulative healing rate of gastric ulcers as confirmed by upper gastrointestinal endoscopy at 8 weeks in patients. Secondary endpoints included ulcer healing rate, symptom recovery, quality of life changes, and safety assessment results. RESULTS: In the per-protocol set, the cumulative healing rate at 8 weeks was 100.00% (146/146) for zastaprazan 20 mg and 97.06% (132/136) for lansoprazole 30 mg, while at week 4, the healing rates were 93.84% (137/146) and 91.91% (125/136), respectively. Zastaprazan was noninferior to lansoprazole in ulcer healing, while the incidence of adverse events was comparable between groups. Gastrin levels increased during the treatment and declined after the treatment in both groups. CONCLUSIONS: An 8-week therapy involving zastaprazan 20 mg demonstrated noninferiority to lansoprazole 30 mg in the cumulative rate of healing of gastric ulcers at 8 weeks, and the two demonstrated similar safety profiles. (ClinicalTrials.gov identifier NCT05448001).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。